| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite does not have a direct biological target, as it is a synthetic intermediate used for oligonucleotide synthesis. However, its parent nucleoside, 5-fluoro-2'-deoxycytidine, is a nucleoside antimetabolite that can be incorporated into DNA and interfere with DNA synthesis and repair. 5-Fluoro-2'-deoxycytidine is a cytidine analog that, upon incorporation into DNA, can inhibit DNA methylation and have anticancer effects. When incorporated into oligonucleotides, the compound can be used to study the effects of 5-fluoro-2'-deoxycytidine on DNA structure, function, and epigenetic regulation. The DMTr and phosphoramidite groups are protecting and activating groups that enable the compound to be used in standard phosphoramidite-based oligonucleotide synthesis.
|
|---|---|
| ln Vitro |
In vitro activity of DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite is not characterized as a pharmacological agent, as it is a synthetic building block for oligonucleotide synthesis. Its primary in vitro application is in the chemical synthesis of modified oligonucleotides. The compound is used in solid-phase oligonucleotide synthesis, where it is coupled to a growing oligonucleotide chain through phosphoramidite chemistry. The resulting oligonucleotides containing 5-fluoro-2'-deoxycytidine can then be used in various biological assays to study the effects of this nucleoside analog on DNA function. The compound itself is not typically evaluated for biological activity, as it is a research tool for oligonucleotide synthesis.
|
| ln Vivo |
In vivo activity is not applicable to DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite, as the compound is a synthetic building block for oligonucleotide synthesis rather than a directly administered drug. The compound is not used in animal studies in its native form. Instead, the modified oligonucleotides synthesized from this compound may be evaluated in vivo for their therapeutic effects. However, the specific in vivo activity of DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite itself has not been reported. The compound is intended for research use only and is not intended for human use. Its role is limited to the chemical synthesis of modified oligonucleotides that may have biological activity.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assay protocols are not directly applicable to DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite, as the compound is a synthetic intermediate rather than a pharmacologically active compound. The compound is primarily characterized by analytical techniques such as HPLC, NMR, and mass spectrometry to confirm identity and purity. In the context of oligonucleotide synthesis, the compound's reactivity and coupling efficiency are assessed using standard phosphoramidite coupling protocols. The resulting modified oligonucleotides can be characterized by mass spectrometry and HPLC to confirm sequence and modification incorporation. The compound is not typically evaluated in enzyme or receptor binding assays.
|
| Cell Assay |
In vitro cell-based assay protocols are not directly applicable to DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite, as the compound is a synthetic building block rather than a biologically active compound. The compound is not typically tested in cell-based assays in its native form. Instead, the modified oligonucleotides synthesized from this compound are evaluated in cell-based assays for their biological effects. A standard protocol for evaluating modified oligonucleotides would involve treating cells with the oligonucleotides (e.g., antisense oligonucleotides or aptamers) and assessing effects on gene expression, cell proliferation, or other relevant endpoints. However, these assays are performed on the final oligonucleotides, not on DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite itself.
|
| Animal Protocol |
In vivo animal experimental protocols are not applicable to DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite, as the compound is a synthetic building block rather than a directly administered drug. The compound is not used in animal studies in its native form. Instead, modified oligonucleotides synthesized from this compound may be evaluated in vivo for their therapeutic effects. A hypothetical protocol for evaluating a modified oligonucleotide in vivo would involve administering the oligonucleotide to animal models of disease via appropriate routes (e.g., intravenous, subcutaneous, or local injection). Endpoints would include assessment of target gene modulation, therapeutic efficacy, and pharmacokinetic parameters. However, these studies are performed on the final oligonucleotides, not on DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite as a directly administered compound, as it is a synthetic building block rather than a drug. The compound is not intended for in vivo administration, and its PK properties have not been characterized. The compound has a molecular weight of 747.79 and a molecular formula of C39H47FN5O7P. It is soluble in DMSO at 140 mg/mL (187.22 mM). The compound should be stored at -80°C, protected from light, and stored under nitrogen. Specific PK parameters such as half-life, Cmax, AUC, bioavailability, volume of distribution, and clearance have not been reported.
|
| References | |
| Additional Infomation |
DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite (compound 1B) is a research-grade compound that serves as a phosphoramidite of 5-Fluoro-2'-deoxycytidine for oligonucleotide synthesis. It is a nucleoside antimetabolite/analog used as a building block for the synthesis of modified oligonucleotides containing 5-fluoro-2'-deoxycytidine. The compound has not entered clinical trials and is not approved for any therapeutic indication. Its mechanism of action is indirect: when incorporated into oligonucleotides, the 5-fluoro-2'-deoxycytidine moiety can interfere with DNA synthesis and methylation. The compound is available exclusively for research purposes and is not intended for diagnostic, therapeutic, or human applications.
|
| CAS # |
143774-48-5
|
|---|---|
| Appearance |
Off-white to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~140 mg/mL (~187.22 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
